The Institute for Clinical and Economic Review (ICER) on Friday, Feb. 15, released its Final New Evidence Update for Regeneron and Sanofi's alirocumab (Praluent), which is used to treat high cholesterol. According to a press release, the update factors in further analysis of the ODYSSEY Outcomes […]
ICER Sets Out Against Unjustified Price Increases in New Report
The Institute for Clinical and Economic Review (ICER) is targeting unjustified price increases (UPIs) as it looks to expand its focus beyond quality-adjust life year (QALY) analysis, Pharmaceutical Executive reports. The nonprofit recently released a draft protocol for a new annual report that will […]
Report: ICER’s International Push Signals Dedication to Improved HTA
The Institute for Clinical and Economic Review's (ICER) recently-announced global initiative to create new and improved value-based pricing strategies is a "clear signal of the internationalization and desire for harmonization of HTA," according to a recent article published on Pharmaceutical […]
ICER Announces International Partnership to Develop New Assessment Methods
The Institute for Clinical and Economic Review (ICER) on Wednesday, Jan. 23, announced a global initiative aimed at creating new, alternative methods for evaluating innovative therapies and recommending value-based pricing benchmarks. According to a press release, the organization will work with a […]
ICER Plans New Annual Report on Price Increases
The Institute for Clinical and Economic Review (ICER) this week released a report outlining a new annual review which will look to determine whether significant price increases on prescription drugs are supported by clinical evidence. The "Unsupported Price Increase" report remains in the planning […]
ICER Outlines Planned Review of DMD Treatments
The Institute for Clinical and Economic Review on Friday released a report outlining a planned review of Duchenne muscular dystrophy treatments. ICER plans to review Sarepta Therapeutics' eteplirsen and golodirsen, and PTC Therapeutics' deflazacort. While the Food and Drug Administration has […]
ICER President Discusses Group’s Mission
The Washington Examiner caught up with Institute for Clinical and Economic Review (ICER) President Steven Pearson to discuss the group's vision and future. Pearson during the interview said while criticism against ICER is "never ... in short supply," the need for an independent reviewer is […]
ICER Set to Evaluate Treatments for Duchenne Muscular Dystrophy
The Institute for Clinical and Economic Review on Thursday, Dec. 13, announced a planned evaluation of the comparative clinical effectiveness and value of treatments for Duchenne muscular dystrophy (DMD). ICER says the assessment will spotlight Sarepta Therapeutics' eteplirsen and golodirsen. While […]
ICER Report Suggests Value-Based Pricing for Extended-Release Drugs for Addiction
The Institute for Clinical and Economic Review's (ICER) latest report encourages manufacturers of extended-release medications for addiction treatment to align their prices with the drug's clinical value, InsideHealthPolicy reports. ICER in its report also pushes payers and lawmakers to avoid […]
ICER Seeks Nominations for Independent Review Groups
The Institute for Clinical and Economic Review (ICER) announced Wednesday, Dec. 5, that it was seeking nominations for its three independent evidence review groups. Nominations are sought for all three of the following groups:The California Technology Assessment Forum (CTAF); The Midwest […]
